Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2024 11:26 ET | Source: Research and Markets

Pre-Eclampsia Pipeline Insights Report 2024 Featuring Gmax Biopharm, Vicore Pharma, and Comanche Biopharma

Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Pre-Eclampsia - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report report provides comprehensive...
January 17, 2024 06:00 ET | Source: Comanche Biopharma

Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia

Comanche Biopharma closes oversubscribed $75 Million Series B financing to advance first treatment targeting a root cause of preeclampsia.
June 01, 2023 11:23 ET | Source: Research and Markets

Global Polycystic Ovary Syndrome Treatment Market Report 2023: Sector is Expected to Reach $1.5 Billion by 2030 at a CAGR of 4.9%

Dublin, June 01, 2023 (GLOBE NEWSWIRE) -- The "Polycystic Ovary Syndrome Treatment Market, By Drug Class, By Distribution Channel, By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 -...
May 24, 2023 04:28 ET | Source: Research and Markets

Pre-Eclampsia - Pipeline Insight, 2023: Featuring Analysis of Key Projects from Kyowa Kirin, Gmax Biopharm and Vicore Pharma

Dublin, May 24, 2023 (GLOBE NEWSWIRE) -- The "Pre-Eclampsia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights...
August 16, 2022 08:24 ET | Source: Fortune Business Insights

With 2.2% CAGR, Preeclampsia Diagnostics Market Size worth USD 1.24 Billion by 2029

Pune, India, Aug. 16, 2022 (GLOBE NEWSWIRE) -- The global preeclampsia diagnostics market size was valued at USD 1.03 billion in 2021 and reached USD 1.07 billion in 2022. The market is expected to...
September 14, 2021 07:30 ET | Source: Progenity, Inc.

Progenity Announces Patent Granted by USPTO for its Preeclampsia Rule-Out Test

SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the United States Patent and Trademark Office (USPTO) has...
July 29, 2021 07:30 ET | Source: Progenity, Inc.

Progenity Announces Successful Completion of Clinical Validation Study and Achievement of the Primary Endpoint for its Preeclampsia Rule-Out Test

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today successful completion of the validation study for its Preecludia™...
June 02, 2021 07:00 ET | Source: Progenity, Inc.

Progenity Launches Strategic Transformation into Biotech Company, Eliminating Costs of Progenity Genetics Lab and Focusing on Robust, Innovative R&D Pipeline

Closure of genetics lab and other operational improvements expected to result in approximately 70% reduction of annual capital required for operations – from more than $180 million currently to...
May 25, 2021 07:30 ET | Source: Progenity, Inc.

Sean Lavin, MD, Joins Progenity as Vice President, Business Development, Strategy, and Investor Relations

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the appointment of Sean Lavin, M.D. as Vice President, Business...
May 21, 2021 07:30 ET | Source: Progenity, Inc.

Progenity Joins Global Call to Raise Awareness of Preeclampsia in Pregnancy on World Preeclampsia Day – May 22nd

SAN DIEGO, May 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...

Next Page keyboard_arrow_right